Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Non-Small-Cell Lung 2Neoplasms, Second Primary 1Leukemia, Myeloid, Chronic-Phase 1Gastro Intestinal Stromal Tumor 1Congenital Abnormalities 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 59Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 13Drug Therapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5Antineoplastic Agents 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Neoplasms × Tyrosine Kinase Inhibitors × Clear all
NCT04151342 2025-12-03

CARMA-BROS

University Health Network, Toronto

Recruiting
5,500 enrolled

Congenital Abnormalities, Neoplasms, Neoplasms, Second Primary

NCT01098500 2017-05-30

Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

GlaxoSmithKline

Completed
3,800 enrolled 19 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡